Modified MIS Protein Cleavage Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of recombinant human Mullerian Inhibiting Substance (MIS) proteins is hindered by inefficient cleavage and low yield, making it challenging for clinical use, particularly in treating cancers and neurodegenerative diseases, due to complex maturation processes and proteolytic degradation.
Innovation Solution
Modifying the MIS protein sequence with a modified Kex cleavage site and substituting the native leader sequence with that of human serum albumin, combined with the addition of a FLAG tag for purification, enhances cleavage efficiency and bioactivity, increasing the yield of bioactive protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the native MIS leader sequence and cleavage site are used, then the protein structure is natural, but cleavage efficiency is low and production yield is limited
Solution Approach 1:
The patent modifies the cleavage site sequence from the native RAQR/S to a furin/kex2 RARR/S consensus site, changing the biochemical parameters of the cleavage process. This parameter change optimizes recognition by host cell proteases, dramatically improving cleavage efficiency and production yield of bioactive MIS protein.
Solution Approach 2:
The patent introduces a heterologous leader sequence (human serum albumin leader sequence) as an intermediary element that facilitates more efficient processing. This foreign leader sequence serves as a better substrate for cellular signal peptidases, indirectly improving the overall cleavage efficiency and yield of the target MIS protein.
2Productivity
If extensive modifications are made to improve cleavage and yield, then production efficiency increases, but protein purification becomes more complex
Solution Approach 1:
The patent introduces a FLAG tag as a purification intermediary - a short epitope tag that can be easily recognized by affinity chromatography resins. This tag serves as a handle for purifying the modified MIS protein, simplifying the purification process despite other modifications made to the protein sequence.
3Reliability
If the MIS protein is produced for therapeutic use, then clinical application is enabled, but proteolytic degradation and low bioactivity reduce effectiveness
Solution Approach 1:
The modified RARR/S cleavage site creates a more specific and efficient cleavage event that produces the correct bioactive fragment with defined boundaries. This precise cleavage reduces aberrant proteolytic processing and degradation, enhancing the reliability and bioactivity of the therapeutic protein.
Solution Approach 2:
The heterologous leader sequence performs the preliminary function of efficient signal peptide cleavage in the host cell, ensuring proper maturation of the MIS protein before secretion. This preliminary processing action ensures the protein is correctly prepared for therapeutic use, reducing subsequent degradation issues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified recombinant MIS protein demonstrates improved cleavage efficiency, increased bioactivity, and higher production yields, effectively inducing Mullerian duct regression and showing potential in treating cancers and neurodegenerative diseases like amyotrophic lateral sclerosis.
Implementation Method 1
the 140 kilodalton (kDa) disulfide-linked homodimer of MIS is proteolytically cleaved to generate its active C-terminal fragments
Implementation Method 2
a FLAG Tag... to facilitate its purification
Data Source
AI summary
The present invention relates to methods to treat a neurodegenerative disease or disorder, e.g., a motor neuron disease in a subject, whereby the subject is administered a recombinant human Mullerian Inhibiting Substance (MIS) protein as disclosed herein, wherein the recombinant human MIS protein comprises a modified Kex cleavage site for increased cleavage. The recombinant human MIS protein can be produced from a pre-proprotein comprising a non-MIS leader sequence or a functional fragment thereof in place of the MIS leader sequence.